Method for obtaining of stabilized pharmaceutical composition as aqueous solution

FIELD: pharmacology.

SUBSTANCE: invention relates to a method for preparation of a stabilized pharmaceutical composition in the form of an aqueous solution which can be used to prepare a drug for intravenous administration containing succinic acid, nicotinamide, inosine and riboflavin mononucleotide sodium as active components and having cytoprotective properties. In the method for preparation of a stabilized pharmaceutical composition in the form of an aqueous solution containing succinic acid, inosine, nicotinamide, riboflavin sodium mononucleotide as active components, by dissolving them in water with subsequent sterilizing filtration, the followin is further added to the composition as a stabilizing agent: one or more pharmaceutically acceptable components selected from the group consisting of sodium hydroxide, trisoxymethylaminomethane (TRIS), ethanolamine, diethanolamine, sodium carbonate, meglumine, to obtain a stable solution with pH in the range of 6.0 to 8.0 in the following ratio, wt %: succinic acid 5.00-12.50; inosine 1.00-2.40; nicotinamide 0.50-1.20; riboflavin mononucleotide sodium 0.10-0.24; stabilizing agent 3.21-51.30; water to 100.0%, and further thermal sterilisation of the solution at a temperature of 100C and exposure time of 8 min to 116C and exposure time of 2 min.

EFFECT: increased method application safety due to thermal sterilisation.

3 cl, 96 ex, 5 tbl

 



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a pharmaceutical composition for control of pain accompanying individual's joint diseases containing hyaluronic acid, which is cross-linked by cycling a double bond in a group of cinnamic acid in partially amidated hyaluronic acid presented by formula (1) to form a cyclobutane cycle, wherein in the above formula, Ar represents a phenyl group, n is equal to an integer 2 or 3; HA represents a carboxy residue of hyaluronic acid, and m represents a relation of amidation of hyaluronic acid to all the carboxyl groups and is equal to 3-50% in relation to all the carboxyl groups, and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition represents a product for injection, wherein the pharmaceutical composition represents the product for injection, wherein the amount of the cross-linked hyaluronic acid makes 1 wt % at the total amount of the product for injection, wherein a single dose of the product for injection makes 2-3 ml, wherein the pharmaceutical composition represents a single-use preparation, which is administered every 13 weeks and more.

EFFECT: invention provides the extremely long analgesic action after the single administration, earlier onset of the analgesic action.

15 cl, 1 dwg, 5 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and represents medication, possessing virucidal activity, for preventive and therapeutic treatment of viral infections, caused by virus of herpesviridae family, characterised by the fact that said medication contains pyroxican in carrier substance.

EFFECT: invention provides extension of arsenal of means, possessing virucidal activity.

7 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a microbiologically stable pharmaceutical composition containing an active agent specified in prostaglandins, and a carrier. The carrier contains an aqueous electrochemically activated saline containing 1 to 500 mg/l of free chlorine and having an oxidation-reduction potential from +150 to +1350 mV. The active agent is present in a phase separated from the electrochemically activated saline; the electrochemically activated saline is a hypochlorite solution.

EFFECT: invention refers to using the pharmaceutical composition for treating and/or preventing dry eye syndrome and for cleansing contact lenses.

14 cl, 5 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relate to field of pharmaceutics and deal with pharmaceutically stable compositions, which contain human antibody, specifically bound with human interleukine 6 (hIL-6R) receptor, where said human antibody is contained in concentration from 5 to 200 mg/ml and includes variable region of light chain with amino acid succession SEQ ID NO:26, histidine, arginine, sucrose, polysorbate.

EFFECT: group of inventions ensure considerable degree of antibody stability after storing for several months.

22 cl, 8 ex, 28 tbl, 4 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to an injectable therapeutic anti-cancer formulation administered into cancer cells directly. The formulation contains 5-25% (wt/vol) of hydroxychloroquine or hydroxychloroquine sulphate, Lidocaine concentrated 1-2% (wt/vol), Riboflavin concentrated 0.1-0.5% (wt/vol) and physiologic saline.

EFFECT: invention provides the formulation which exhibits cytotoxic effect on the cancer cells without involving normal cells, and which is administered into the cancer cells directly.

2 cl, 3 tbl, 4 dwg, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a pharmaceutical composition in the form of a liquid solution for nasal administration of spray containing naltrexone in an amount of 0.005-0.02 wt/vl %.

EFFECT: invention provides eliminating the undesired side effects with preserving naltrexone activity.

6 cl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine. Described is medical form for transmucousal per oral introduction of, at least, one active substance of antispasmodic and/or analgesic action, which contains said active substance in form of base and/or in form of salt, water-alcohol solution, with alcoholic content, at least, 35 of alcohol by weight, with said active substance being present in water-alcohol solution in condition of stable and complete dissolution. Invention also relates to method of said medical form preparation and its application for treating spastic attacks.

EFFECT: medical form makes it possible to realise instantaneous transmucousal per oral introduction.

10 cl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely represents a method for the therapy of respiratory symptom. The method involves administering a liquid composition containing a gel former and/or a mucoactive polymer, a non-menthol cooling substance; and contacting the oral mucosa with the liquid composition. The invention also describes liquid compositions applicable in the method for the therapy of a respiratory disease.

EFFECT: implementing the method provides improving the cooling properties of the cooling agent N-(4-cyanomethylphenyl)-n-menthane carboxamide in the liquid composition by combining the non-menthol cooling substance with the gel former.

14 cl, 2 tbl, 5 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to the field of pharmaceutics and deals with a pharmaceutical composition, which contains feline erythropoietin as an active ingredient, to which two or more polyethyleneglycol molecules with a non-branched chain are attached, with a water-soluble long-chain molecule having the molecular weight, constituting not less than 30 kDa and producing the haemopoietic effect. A haemopoietic medication and a medication for the treatment of anaemia are based on the said composition.

EFFECT: group of inventions provides the haemopoietic effect, which lasts for not less than seven days, when introduced to humans and/or animals.

8 cl, 4 dwg, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention represents a composition for preventing and treating allergic conjunctivitis and keratoconjunctivitis, containing cromoglicic acid, boric acid and water-soluble polymers specified in a group of: carbomer, hypromellose, macrogol and polyvinylpyrrolidone with the components of the composition taken in specific relations, g in 1 ml of the mixture.

EFFECT: invention provides the better reduction of the inflammatory process and symptoms of the disease; there are also ensured ease of use with a smaller frequency of administration, prolonged action and no side effects.

5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutics. Gel form of azelaic acid is described. Gel form includes micronized azelaic acid and additional substances: benzoic acid, disodium edetate, carbomer Carbopol 980, propylene glycol, sodium hydroxide, glycoceramides purified, isopropylmiristate, polysorbate 20, purified water.

EFFECT: invention is provided by obtaining stable medication in form of gel, which does not produce local irritating action in case of long-term on-skin applications.

11 cl, 15 dwg, 5 tbl

FIELD: veterinary medicine.

SUBSTANCE: invention is a method of correction of immunobiochemical status of cows in the prenatal and postpartum periods. The invention comprises the following steps: the dry cows within 10-12 days prior to and 10-12 days after parturation are given orally the composite agent based on organic acids, containing fumaric, ascorbic, succinic and citric acid based on per dose, mg/kg body weight: fumaric acid - 3.0-5.0; ascorbic acid - 4.5-7.5; succinic acid - 6.0-10.0; citric acid - 1.5-2.5, in combination with dualfold intramuscular injection tetrahydrovit 30 days before and on the day of parturation at a dose of 10 ml/head, and threefold intramuscular injection of iron complex 30, 15 days before and on the day of parturation at a dose of 0.2 ml/10 kg bodyweight.

EFFECT: invention provides a correction of immunobiochemical homeostasis at the level providing for physiological parturation and the postpartum period and obtaining viable offspring.

14 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to veterinary and can be applied in pig-breeding for the stimulation of exchange processes, growth activity, prevention of hypomicroelementosis and diarrhoeas of piglets. An energometabolic composition for the stimulation of exchange processes represents a water solution, which contains succinic acid, iodinol, beet molasses and sulphates of iron, copper, cobalt, zinc, with the following component content in 1000 ml of the solution: succinic acid - 10.0 g, iodinol - 250 ml, beet molasses - 300 ml, iron sulphate - 2 g, copper sulphate - 0.1 g, cobalt sulphate - 1 g, zinc sulphate - 0.3 g, water- the remaining part.

EFFECT: application of the invention will make it possible to improve exchange processes in piglets.

4 tbl

FIELD: veterinary medicine.

SUBSTANCE: composition comprises succinic acid, trace elements in the form of sulphates of iron, copper, cobalt, zinc and additionally comprises methionine and beet-root molasses at the following content of components in 1000 ml of an aqueous solution: succinic acid - 5.0 g, beet-root molasses - 150.0 ml, methionine - 2.0 g, ferrous sulphate - 10.0 g, copper sulphate - 0.1 g, cobalt sulphate - 0.5 g, zinc sulphate - 0.5 g.

EFFECT: use of the claimed composition has a positive effect on the immune-metabolic status and growth activity of piglets.

3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: cytoflavin is administered into laboratory animals (rats) daily immediately before overheating in an air laboratory thermostat at +401-2C for 45 minutes. The preparation is administered intraperitoneally in a dose of 100 mg/kg of body weight for 14 days.

EFFECT: higher body adaptability by increasing antioxidant activity and reducing a rate of lipid peroxidation products accumulation with underlying thermal exposure.

4 tbl

FIELD: agriculture.

SUBSTANCE: group of inventions relates to the field of animal husbandry and is intended for stimulation of energy metabolic processes and to the method of prevention of patrimonial pathologies and postnatal diseases at cows. The offered composition for stimulation of energy metabolic processes includes the use of amber acid as an energy stimulator. A carbohydrate component is beet treacle, it is used in the following ratio of components per 1 litre: amber acid - 15 g, beet treacle - 500 g, water - the rest. The offered method includes the administration of the named composition a days before calving and during the first hours after calving.

EFFECT: use of the offered group of inventions allows to provide high power activity in organisms of animals during the predicted periods of risk of development of serious pathobiochemical processes, in particular in prenatal and postnatal periods.

2 cl, 2 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: pharmaceutical composition in the form of a tablet with an erodible matrix, which contains one or more fumaric acid ethers, as well as a rate-controlling agent, representing hydroxypropylcellulose and a binding agent, representing lactose, with the decomposition of the said degradable matrix providing the controlled release of the said fumaric acid ether (ethers).

EFFECT: provision of the controlled release of fumaric acid ether (ethers).

19 cl, 43 ex, 2 tbl, 2 dwg

FIELD: biotechnology.

SUBSTANCE: increase in biocidal and immunobiological action due to the use of distilled water ionised with silver ions and adding into the composition of succinic, ascorbic, citric acid and aethonium.

EFFECT: increase in biocidal immunobiological properties of the antiseptic-stimulant of Dorogov ASD-2F.

6 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: analgesic preparations caused the onset of abuse headache are withdrawn; detoxification therapy, alternative anaesthesia, preventive and behavioural therapy follow. The detoxification therapy represents a 10-day therapeutic course according to the schedule: Cytoflavin 10 ml dissolved in 0.9% NaCl 200 ml is administered intravenously drop-by-drop daily in the morning and evening. Additionally, Milgamma 2.0 ml is injected intramuscularly daily in the morning; Reamberin 200-400 ml is administered intravenously drop-by-drop every second day.

EFFECT: treating the patients with abuse headache and reducing the number of recurrences.

2 ex

FIELD: medicine.

SUBSTANCE: active agent contains a complex of eggshell macro- and microelements in the form of complexonates; it can be used in pharmacology, veterinary science, medicine and food industry as a drug and/or a biologically active additive. The dried eggshell ground to a particle size of no more than 0.09 mm is mixed for 20 minutes with 9-10-fold excess of water heated to 90C, and ethylene diamine disuccinic acid is added in ratio of eggshell:ethylene diamine disuccinic acid as 3.6:1. Excess of water at temperature 20C is added to the solution; after dissolution, the mixture is purified by filtering; the filtrate is evaporated to a constant weight at 100C and ground.

EFFECT: preparing the mineral complex with high biological value and bioavailability.

1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, namely to method of obtaining encapsulated particles of metal salts. Method of obtaining particles of metal salts encapsulated in liposoluble polymer envelope consists in the fact that metal salt, selected from the group: iron sulphate, zinc sulphate, potassium iodide or calcium chloride, is dissolved in water, obtained mixture is dispersed in sodium carboxymethylcellulose in butanol in presence of E472c and mixed, with further addition of ethanol to obtained mixture, obtained suspension is filtered and dried at room temperature, under specified conditions.

EFFECT: method makes it possible to simplify and accelerate process of obtaining microcapsules.

4 ex

Up!